Pdl Biopharma Inc (PDLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2000 | 12-1999 | 12-1998 | 12-1997 | 12-1996 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 647 | -10,333 | -9,500 | -23,875 | -11,796 |
| Depreciation Amortization | 4,198 | 3,538 | 3,690 | 3,244 | 3,242 |
| Accounts payable and accrued liabilities | 185 | -433 | N/A | N/A | N/A |
| Other Working Capital | 1,982 | -3,511 | -1,030 | 1,809 | 1,063 |
| Other Operating Activity | -185 | 20 | 300 | 11,181 | 466 |
| Operating Cash Flow | $6,827 | $-10,719 | $-6,540 | $-7,641 | $-7,025 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -114,821 | -6,436 | N/A | N/A | N/A |
| PPE Investments | -3,355 | -18,490 | -16,750 | -4,565 | -3,669 |
| Other Investing Activity | 0 | 0 | 37,980 | -67,572 | 15,434 |
| Investing Cash Flow | $-118,176 | $-24,926 | $21,230 | $-72,137 | $11,765 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 150,000 | 10,150 | N/A | N/A | N/A |
| Debt Repayment | -369 | -58 | N/A | N/A | N/A |
| Common Stock Issued | 366,121 | 14,784 | N/A | N/A | N/A |
| Other Financing Activity | 0 | 0 | 3,940 | 74,903 | 4,715 |
| Financing Cash Flow | $515,752 | $24,876 | $3,940 | $74,903 | $4,715 |
| Beginning Cash Position | 17,138 | 27,907 | 9,260 | 14,141 | 4,686 |
| End Cash Position | 421,541 | 17,138 | 27,900 | 9,266 | 14,141 |
| Net Cash Flow | $404,403 | $-10,769 | $18,640 | $-4,875 | $9,455 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,827 | -10,719 | -6,540 | -7,641 | -7,025 |
| Capital Expenditure | -3,355 | -18,815 | N/A | N/A | N/A |
| Free Cash Flow | 3,472 | -29,534 | -6,540 | -7,641 | -7,025 |